MRNA-5671

MRNA-5671 is an investigational cancer vaccine developed by Moderna Therapeutics, a biotechnology company specializing in mRNA therapies. The vaccine is designed to target KRAS mutations, which are common in several types of cancer.

Overview

MRNA-5671 is a part of Moderna's proprietary mRNA platform. It is designed to stimulate the body's immune system to recognize and destroy cancer cells carrying specific KRAS mutations. KRAS mutations are found in approximately 25% of all human cancers, including lung cancer, pancreatic cancer, and colorectal cancer.

Mechanism of Action

MRNA-5671 works by delivering mRNA sequences that encode for four different KRAS mutations into the body. These mRNA sequences are encapsulated in lipid nanoparticles to ensure their delivery into cells. Once inside the cells, the mRNA is translated into proteins that mimic the KRAS mutations. These proteins are then presented on the cell surface, where they can be recognized by the immune system. This process is intended to stimulate an immune response against cancer cells carrying the actual KRAS mutations.

Clinical Trials

As of 2021, MRNA-5671 is in Phase 1 clinical trials. These trials are evaluating the safety, tolerability, and efficacy of the vaccine in patients with KRAS-mutant cancers. The trials are also investigating the optimal dosing and administration schedule for the vaccine.

Potential Impact

If successful, MRNA-5671 could provide a new treatment option for patients with KRAS-mutant cancers. Currently, these cancers are difficult to treat and often have poor prognoses. By targeting the underlying genetic mutations driving these cancers, MRNA-5671 could potentially improve patient outcomes.

See Also

• Cancer vaccine
• Moderna Therapeutics
• mRNA
• KRAS